Improvement of endothelial function in a murine model of mild cholesterol-induced atherosclerosis by mineralocorticoid antagonism

Atherosclerosis

Volumn 251, Issue , 2016, Pages 291-298

  Kratz, Mario T ^a   Schirmer, Stephan H ^a   Baumhäkel, Magnus ^a   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Atherosclerosis; Corpora cavernosa; Endothelial dysfunction; Erectile dysfunction; Oxidative stress; Vascular and penile fibrosis

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; COLLAGEN; EPLERENONE; RAMIPRIL; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID; MINERALOCORTICOID ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA SINUS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CELL FUNCTION; CHOLESTEROL INDUCED ATHEROSCLEROSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS CAVERNOSUM; ENDOTHELIUM CELL; EXPERIMENTAL ATHEROSCLEROSIS; HEART RATE; MACROPHAGE; MALE; MOUSE; MURINE MODEL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL; AORTA; APOLIPOPROTEIN E KNOCKOUT MOUSE; ATHEROSCLEROSIS; BLOOD PRESSURE; ERECTILE DYSFUNCTION; METABOLISM; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; AORTA; ATHEROSCLEROSIS; BLOOD PRESSURE; CHOLESTEROL; ENDOTHELIUM, VASCULAR; ERECTILE DYSFUNCTION; HEART RATE; MALE; MICE; MICE, KNOCKOUT, APOE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MINERALOCORTICOIDS; OXIDATIVE STRESS;

EID: 84978397806     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.06.018     Document Type: Article

References (38)

1. [1] Ferrario, C.M., Schiffrin, E.L., Role of mineralocorticoid receptor antagonists in cardiovascular disease. Circ. Res. 116 (2015), 206–213.
2. [2] Feldman, R.D., Gros, R., Vascular effects of aldosterone: sorting out the receptors and the ligands. Clin. Exp. Pharmacol. Physiol. 40 (2013), 916–921.
3. [3] Romagni, P., Rossi, F., Guerrini, L., Quirini, C., Santiemma, V., Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 166 (2003), 345–349.
4. [4] Noda, K., Kobara, M., Hamada, J., Yoshifuji, Y., Shiraishi, T., Tanaka, T., Wang, J., Toba, H., Nakata, T., Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts. J. Cardiovasc. Pharmacol. 60 (2012), 140–149.
5. [5] Jain, G., Campbell, R.C., Warnock, D.G., Mineralocorticoid receptor blockers and chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4 (2009), 1685–1691.
6. [6] Miana, M., de Las Heras, N., Rodriguez, C., Sanz-Rosa, D., Martin-Fernandez, B., Mezzano, S., Lahera, V., Martinez-Gonzalez, J., Cachofeiro, V., Effect of eplerenone on hypertension-associated renal damage in rats: potential role of peroxisome proliferator activated receptor gamma (PPAR-γ). J. Physiol. Pharmacol. 62 (2011), 87–94.
7. [7] Schiffrin, E.L., Franks, D.J., Gutkowska, J., Effect of aldosterone on vascular angiotensin II receptors in the rat. Can. J. Physiol. Pharmacol. 63 (1985), 1522–1527.
8. [8] Timmermans, P.B., Wong, P.C., Chiu, A.T., Herblin, W.F., Benfield, P., Carini, D.J., Lee, R.J., Wexler, R.R., Saye, J.A., Smith, R.D., Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45 (1993), 205–251.
9. [9] Böhm, M., Baumhäkel, M., Probstfield, J.L., Schmieder, R., Yusuf, S., Zhao, F., Koon, T., ONTARGET/TRANSCEND ED-investigators, sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing telmisartan Alone and in combination with ramipril global endpoint trial/telmisartan randomized AssessmeNT study in ACE-INtolerant subjects with cardiovascular disease (ONTARGET/TRANSCEND). Am. Heart J. 154 (2007), 94–101.
10. [10] Esposito, K., Giugliano, F., Di Palo, C., Giugliano, G., Marfella, R., D'Andrea, F., D'Armiento, M., Giugliano, D., Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 291 (2004), 2978–2984.
11. [11] Böhm, M., Baumhäkel, M., Teo, K., Sleight, P., Probstfield, J., Gao, P., Mann, J.F., Diaz, R., Dagenais, G.R., Jennings, G.L., Liu, L., Jansky, P., Yusuf, S., ONTARGET/TRANSCEND erectile dysfunction substudy investigators, erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: the ONgoing telmisartan Alone and in combination with ramipril global endpoint trial/telmisartan randomized AssessmeNt study in ACE iNtolerant subjects with cardiovascular disease (ONTARGET/TRANSCEND) trials. Circulation 121 (2010), 1439–1446.
12. [12] S1, Wassmann, Czech, T., van Eickels, M., Fleming, I., Böhm, M., Nickenig, G., Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 110 (2004), 3062–3067.
13. [13] Laufs, U., Wassmann, S., Czech, T., Münzel, T., Eisenhauer, M., Böhm, M., Nickenig, G., Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25 (2005), 809–814.
14. [14] Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., Palensky, J., Wittes, J., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341 (1999), 709–717.
15. [15] Zannad, F., McMurray, J.J., Krum, H., van Veldhuisen, D.J., Swedberg, K., Shi, H., Vincent, J., Pocock, S.J., Pitt, B., EMPHASIS-HF Study Group, Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl. J. Med. 364 (2011), 11–21.
16. [16] B1, Pitt, Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., Gatlin, M., Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators, eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348 (2003), 1309–1321.
17. [17] Young, M.J., Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation. Curr. Opin. Nephrol. Hypertens. 17 (2008), 174–180.
18. [18] Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., Dagenais, G., Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342 (2000), 145–153.
19. [19] Dagenais, G.R., Pogue, J., Fox, K., Simoons, M.L., Yusuf, S., Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368 (2006), 581–588.
20. [20] Schlimmer, N., Kratz, M., Böhm, M., Baumhäkel, M., Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis. Br. J. Pharmacol. 163 (2011), 804–814.
21. [21] Libby, P., Inflammation in atherosclerosis. Nature 420 (2002), 868–874.
22. [22] Baumhäkel, M., Custodis, F., Schlimmer, N., Laufs, U., Böhm, M., Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice. Atherosclerosis 212 (2010), 55–62.
23. [23] Baumhäkel, M., Custodis, F., Schlimmer, N., Laufs, U., Böhm, M., Improvement of endothelial function of the corpus cavernosum in apolipoprotein E knockout mice treated with irbesartan. J. Pharmacol. Exp. Ther. 327 (2008), 692–698.
24. [24] ONTARGET Investigators, Yusuf, S., Teo, K.K., Pogue, J., Dyal, L., Copland, I., Schumacher, H., Dagenais, G., Sleight, P., Anderson, C., Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358 (2008), 1547–1559.
25. [25] Velazquez, E.J., Pfeffer, M.A., McMurray, J.V., Maggioni, A.P., Rouleau, J.L., Van de Werf, F., Kober, L., White, H.D., Swedberg, K., Leimberger, J.D., Gallo, P., Sellers, M.A., Edwards, S., Henis, M., Califf, R.M., VALIANT Investigators, VALsartan in Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Eur. J. Heart Fail. 5 (2003), 537–544.
26. [26] Montalescot, G., Pitt, B., Lopez de Sa, E., Hamm, C.W., Flather, M., Verheugt, F., Shi, H., Turgonyi, E., Orri, M., Vincent, J., Zannad, F., REMINDER Investigators, REMINDER Investigators, Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the randomized Double-Blind Reminder Study. Eur. Heart J. 35 (2014), 2295–2302.
27. [27] Aikawa, M., Rabkin, E., Okada, Y., Voglic, S.J., Clinton, S.K., Brinckerhoff, C.E., Sukhova, G.K., Libby, P., Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 97 (1998), 2433–2444.
28. [28] Rickard, A.J., Morgan, J., Chrissobolis, S., Miller, A.A., Sobey, C.G., Young, M.J., Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension 63 (2014), 1033–1040.
29. [29] Bauersachs, J., Jaisser, F., Toto, R., Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases. Hypertension 65 (2015), 257–263.
30. [30] Laufs, U., Wassmann, S., Czech, T., Münzel, T., Eisenhauer, M., Böhm, M., Nickenig, G., Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25 (2005), 809–814.
31. [31] Baumhäkel, M., Schlimmer, N., Büyükafsar, K., Arikan, O., Böhm, M., Nebivolol, but not metoprolol, improves endothelial function of the corpus cavernosum in apolipoprotein e-knockout mice. J. Pharmacol. Exp. Ther. 325 (2008), 818–823.
32. [32] Schirmer, S.H., Degen, A., Baumhäkel, M., Custodis, F., Schuh, L., Kohlhaas, M., Friedrich, E., Bahlmann, F., Kappl, R., Maack, C., Böhm, M., Laufs, U., Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis. Eur. Heart J. 33 (2012), 1223–1231.
33. [33] Kaiser, D.R., Billups, K., Mason, C., Wetterling, R., Lundberg, J.L., Bank, A.J., Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J. Am. Coll. Cardiol. 43 (2004), 179–184.
34. [34] Solomon, H., Man, J.W., Jackson, G., Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 89 (2003), 251–253.
35. [35] Heitzer, T., Schlinzig, T., Krohn, K., Meinertz, T., Münzel, T., Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 104 (2001), 2673–2678.
36. [36] Bacon, C.G., Mittleman, M.A., Kawachi, I., Giovannucci, E., Glasser, D.B., Rimm, E.B., Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann. Intern Med. 139 (2003), 161–168.
37. [37] Rajagopalan, S., Kurz, S., Münzel, T., Tarpey, M., Freeman, B.A., Griendling, K.K., Harrison, D.G., Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Investig. 97 (1996), 1916–1923.
38. [38] Speel, T.G., Kiemeney, L.A., Thien, T., Smits, P., Meuleman, E.J., Long-term effect of inhibition of the angiotensin-converting enzyme (ACE) on cavernosal perfusion in men with atherosclerotic erectile dysfunction: a pilot study. J. Sex. Med. 2 (2005), 207–212.